RTP-026

Phase 2Small molecule

RResoTher Pharma

RTP-026 is one of 49 small molecule programs targeting Myocardial Infarction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionRecruiting

Myocardial InfarctionPhase 2

Recruiting

Competition

Competitive Landscape

89 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Praluent

Regeneron

Approved

1 2

Crestor

AstraZeneca

Approved

1 3

Adenocard

Niacor

Neoral

Alka-Seltzer

1 7

Coreg

Akero Therapeutics

Approved

1 8

Reglan

IIstituto Clinico Humanitas

Approved

1 9

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Benicar

CCosette Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myocardial Infarction1 trial

A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)

Recruiting·RResoTher Pharma·Phase 2·NCT06465303·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RTP-026. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RTP-026 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RTP-026. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ResoTher Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RResoTher Pharma

RTP-026

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News